EP Patent

EP1461026A2 — Method for treating ocular hypertension

Assigned to Merck Frosst Canada and Co · Expires 2004-09-29 · 22y expired

What this patent protects

This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions that are related to elevated intraocular pressure in the eye of a patient. This invention als…

USPTO Abstract

This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions that are related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

Drugs covered by this patent

Patent Metadata

Patent number
EP1461026A2
Jurisdiction
EP
Classification
—
Expires
2004-09-29
Drug substance claim
No
Drug product claim
No
Assignee
Merck Frosst Canada and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.